Cambridge, MA (U.S.) and Lyon (France), June 5, 2023 – ERYTECH Pharma (Nasdaq & Euronext: a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that Akkadian Partners has initiated legal proceedings to obtain the postponement of the vote on the merger…Read More
ERYTECH announces that Akkadian has initiated proceedings to postpone the vote on the merger with Pherecydes
